Free shipping over €250 · Tracked, discreet delivery in Europe

Senolytic peptide

FOXO4-DRI

Research compoundNot yet reviewedPeptideIn the catalog

In short: A modified peptide designed to disrupt the FOXO4 and p53 interaction in senescent cells. Studied in aged mice.

Regulatory status

  1. Cosmetic ingredient
  2. Research compound
  3. In clinical trials
  4. Approved medicine

Not approved as a medicine by the FDA or the EMA. Some are registered in individual countries. Supplied for laboratory research only.

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Common questions

Is FOXO4-DRI an approved medicine?

Research compound. Not approved as a medicine by the FDA or the EMA. Some are registered in individual countries. Supplied for laboratory research only.

How much human research is there on FOXO4-DRI?

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Does UU supply FOXO4-DRI?

Yes, as premium-grade research material for laboratory use. Every batch is tested by an independent lab and the certificate of analysis is published.

More in Cells & ageing

Back to the library
  • Researchuu

    Pinealon

    Short bioregulator peptide

    Preclinical
  • Researchuu

    Glutathione

    Antioxidant tripeptide

    Early human data
  • Researchuu

    MOTS-c

    Mitochondrial-derived peptide

    Preclinical
  • Approveduu

    SS-31

    Mitochondria-targeted tetrapeptide

    Human trials
  • Researchuu

    Epithalon

    Pineal tetrapeptide

    Preclinical
  • Researchuu

    NAD+

    Coenzyme

    Mixed evidence

The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.